Two Novel Bacteriophages Improve Survival in
            <i>Galleria mellonella</i>
            Infection and Mouse Acute Pneumonia Models Infected with Extensively Drug-Resistant
            <i>Pseudomonas aeruginosa</i>

Jeon, Jongsoo; Yong, Dongeun

doi:10.1128/aem.02900-18

Cited by 70 publications

(75 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that applying phages as antimicrobial agents for the control of pathogens is not a new approach, and it has been used since the phage was discovered. For example, it was used in Eastern Europe and the former Soviet Union for a long time, and even today, phages are used in Georgia to treat some infections [65]. Various studies have been conducted on the use of phages in animal models to evaluate the safety and efficacy of phages to counteract both major Gram-positive and Gram-negative clinical pathogens.…”

Section: Phage Therapy For Inhibition Of Mdr P Aeruginosa Biofilm: Imentioning

confidence: 99%

“…These phages were able to remove the host XDR P. aeruginosa biofilms extensively. So, it was suggested that these phages could be used as a biocontrol agent not only to inhibit biofilm formation on medical devices and hospital environments but also to eliminate biofilm-associated infections in the body [65].…”

Section: Phage Therapy For Inhibition Of Mdr P Aeruginosa Biofilm: Imentioning

confidence: 99%

See 1 more Smart Citation

Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review

Chegini

Khoshbayan

Moghadam

et al. 2020

Ann Clin Microbiol Antimicrob

186

101

View full text Add to dashboard Cite

Multi-Drug Resistant (MDR) Pseudomonas aeruginosa is one of the most important bacterial pathogens that causes infection with a high mortality rate due to resistance to different antibiotics. This bacterium prompts extensive tissue damage with varying factors of virulence, and its biofilm production causes chronic and antibiotic-resistant infections. Therefore, due to the non-applicability of antibiotics for the destruction of P. aeruginosa biofilm, alternative approaches have been considered by researchers, and phage therapy is one of these new therapeutic solutions. Bacteriophages can be used to eradicate P. aeruginosa biofilm by destroying the extracellular matrix, increasing the permeability of antibiotics into the inner layer of biofilm, and inhibiting its formation by stopping the quorum-sensing activity. Furthermore, the combined use of bacteriophages and other compounds with anti-biofilm properties such as nanoparticles, enzymes, and natural products can be of more interest because they invade the biofilm by various mechanisms and can be more effective than the one used alone. On the other hand, the use of bacteriophages for biofilm destruction has some limitations such as limited host range, high-density biofilm, sub-populate phage resistance in biofilm, and inhibition of phage infection via quorum sensing in biofilm. Therefore, in this review, we specifically discuss the use of phage therapy for inhibition of P. aeruginosa biofilm in clinical and in vitro studies to identify different aspects of this treatment for broader use.

show abstract

Section: Phage Therapy For Inhibition Of Mdr P Aeruginosa Biofilm: Imentioning

confidence: 99%

Section: Phage Therapy For Inhibition Of Mdr P Aeruginosa Biofilm: Imentioning

confidence: 99%

Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review

Chegini

Khoshbayan

Moghadam

et al. 2020

Ann Clin Microbiol Antimicrob

186

101

View full text Add to dashboard Cite

show abstract

“…Among the seven studies that evaluated phage therapy against pneumonia, three studies targeted P. aeruginosa and two studies each evaluated S. aureus and K. pneumoniae respectively [ 18 , 19 , 24 , 27 , 30 , 31 , 39 ]. All seven studies showed the effectiveness of phage therapy against P. aeruginosa, S. aureus, and K. pneumoniae with a remarkable reduction in bacterial cell population and a significant improvement of survival to varying degrees in a dose-dependent matter.…”

Section: Resultsmentioning

confidence: 99%

Bacteriophage Treatment: Critical Evaluation of Its Application on World Health Organization Priority Pathogens

Al-Ishaq

Skariah

Büsselberg

2020

Viruses

View full text Add to dashboard Cite

Bacteriophages represent an effective, natural, and safe strategy against bacterial infections. Multiple studies have assessed phage therapy’s efficacy and safety as an alternative approach to combat the emergence of multi drug-resistant pathogens. This systematic review critically evaluates and summarizes published articles on phages as a treatment option for Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Enterococcus faecalis infection models. It also illustrates appropriate phage selection criteria, as well as recommendations for successful therapy. Published studies included in this review were identified through EMBASE, PubMed, and Web of Science databases and were published in the years between 2010 to 2020. Among 1082 identified articles, 29 studies were selected using specific inclusion and exclusion criteria and evaluated. Most studies (93.1%) showed high efficacy and safety for the tested phages, and a few studies also examined the effect of phage therapy combined with antibiotics (17.2%) and resistance development (27.6%). Further clinical studies, phage host identification, and regulatory processes are required to evaluate phage therapy’s safety and efficacy and advance their clinical use.

show abstract

“…We sought to determine whether these phages confer therapeutic effects in the context of a PAO1 infection model. The Galleria mellonella larva (waxworm) model is convenient, low cost, and well established for Pseudomonas and other bacterial infections and testing of antimicrobial therapies (26)(27)(28)(29)(30). Importantly, antimicrobial therapies, including phage therapy, that are efficacious in waxworm models of infection generally also show efficacy in mammalian models of infection (29,31).…”

Section: Resultsmentioning

confidence: 99%

Computational Basis for On-Demand Production of Diversified Therapeutic Phage Cocktails

et al. 2020

View full text Add to dashboard Cite

New therapies are necessary to combat increasingly antibiotic-resistant bacterial pathogens. We have developed a technology platform of computational, molecular biology, and microbiology tools which together enable on-demand production of phages that target virtually any given bacterial isolate. Two complementary computational tools that identify and precisely map prophages and other integrative genetic elements in bacterial genomes are used to identify prophage-laden bacteria that are close relatives of the target strain. Phage genomes are engineered to disable lysogeny, through use of long amplicon PCR and Gibson assembly. Finally, the engineered phage genomes are introduced into host bacteria for phage production. As an initial demonstration, we used this approach to produce a phage cocktail against the opportunistic pathogen Pseudomonas aeruginosa PAO1. Two prophage-laden P. aeruginosa strains closely related to PAO1 were identified, ATCC 39324 and ATCC 27853. Deep sequencing revealed that mitomycin C treatment of these strains induced seven phages that grow on P. aeruginosa PAO1. The most diverse five phages were engineered for nonlysogeny by deleting the integrase gene (int), which is readily identifiable and typically conveniently located at one end of the prophage. The Δint phages, individually and in cocktails, killed P. aeruginosa PAO1 in liquid culture as well as in a waxworm (Galleria mellonella) model of infection. IMPORTANCE The antibiotic resistance crisis has led to renewed interest in phage therapy as an alternative means of treating infection. However, conventional methods for isolating pathogen-specific phage are slow, labor-intensive, and frequently unsuccessful. We have demonstrated that computationally identified prophages carried by near-neighbor bacteria can serve as starting material for production of engineered phages that kill the target pathogen. Our approach and technology platform offer new opportunity for rapid development of phage therapies against most, if not all, bacterial pathogens, a foundational advance for use of phage in treating infectious disease.

show abstract

Two Novel Bacteriophages Improve Survival in Galleria mellonella Infection and Mouse Acute Pneumonia Models Infected with Extensively Drug-Resistant Pseudomonas aeruginosa

Cited by 70 publications

References 73 publications

Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review

Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review

Bacteriophage Treatment: Critical Evaluation of Its Application on World Health Organization Priority Pathogens

Computational Basis for On-Demand Production of Diversified Therapeutic Phage Cocktails

Contact Info

Product

Resources

About